​

Leap Therapeutics (LPTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

LPTX Stock Forecast

Leap Therapeutics (LPTX) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $5.50, with a high of $5.50 and a low of $5.50. This represents a 1209.52% increase from the last price of $0.42.

- $1 $2 $3 $4 $5 $6 High: $5.5 Avg: $5.5 Low: $5.5 Last Closed Price: $0.42

LPTX Stock Rating

Leap Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 1 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 6 Strong Sell Sell Hold Buy Strong Buy

LPTX Price Target Upside V Benchmarks

TypeNameUpside
StockLeap Therapeutics1209.52%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.42$0.42$0.42
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25--1--1
May, 25--1--1
Apr, 25--1--1
Mar, 251-1--2
Feb, 251-2--3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 14, 2024Swayampakula RamakanthH.C. Wainwright$5.50$2.8394.35%1209.52%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 28, 2024Rodman & RenshawBuyinitialise
May 14, 2024H.C. WainwrightBuyBuyhold
Nov 14, 2023Raymond JamesOutperformOutperformhold
Nov 11, 2022Raymond JamesOutperformOutperformhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.64$-4.73$-4.82$-3.98$-1.81----
Avg Forecast$-6.40$-4.88$-4.88$-3.61$-1.86$-1.28$-1.23$-1.45$-1.59
High Forecast$-6.40$-4.88$-4.88$-3.61$-1.83$-1.07$-0.80$-0.84$-1.59
Low Forecast$-6.40$-4.88$-4.88$-3.61$-1.88$-1.49$-1.89$-2.48$-1.59
Surprise %-27.50%-3.07%-1.23%10.25%-2.69%----

Revenue Forecast

$0 $7M $14M $21M $28M $35M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.50M$1.50M-------
Avg Forecast$1.70M$1.60M$1.50M-$300.00K$34.49M$6.00M$9.88M$22.09M
High Forecast$1.70M$1.60M$1.50M-$300.00K$34.49M$6.00M$9.88M$22.09M
Low Forecast$1.70M$1.60M$1.50M-$300.00K$34.49M$6.00M$9.88M$22.09M
Surprise %-11.76%-6.25%-------

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-27.51M$-40.59M$-54.60M$-81.41M$-67.79M----
Avg Forecast$-130.85M$-99.77M$-99.77M$-73.73M$-37.93M$-26.17M$-27.48M$-33.92M$-32.41M
High Forecast$-130.85M$-99.77M$-99.77M$-73.73M$-37.51M$-21.94M$-16.39M$-17.20M$-32.41M
Low Forecast$-130.85M$-99.77M$-99.77M$-73.73M$-38.34M$-30.40M$-38.58M$-50.64M$-32.41M
Surprise %-78.97%-59.32%-45.28%10.43%78.74%----

LPTX Forecast FAQ

Is Leap Therapeutics stock a buy?

Leap Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Leap Therapeutics is a favorable investment for most analysts.

What is Leap Therapeutics's price target?

Leap Therapeutics's price target, set by 7 Wall Street analysts, averages $5.5 over the next 12 months. The price target range spans from $5.5 at the low end to $5.5 at the high end, suggesting a potential 1209.52% change from the previous closing price of $0.42.

How does Leap Therapeutics stock forecast compare to its benchmarks?

Leap Therapeutics's stock forecast shows a 1209.52% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and outperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Leap Therapeutics over the past three months?

  • June 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Leap Therapeutics’s EPS forecast?

Leap Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.28, marking a -29.28% decrease from the reported $-1.81 in 2024. Estimates for the following years are $-1.23 in 2026, $-1.45 in 2027, and $-1.59 in 2028.

What is Leap Therapeutics’s revenue forecast?

Leap Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $34.49M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $6M, followed by $9.88M for 2027, and $22.09M for 2028.

What is Leap Therapeutics’s net income forecast?

Leap Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-26.17M, representing a -61.40% decrease from the reported $-67.789M in 2024. Projections indicate $-27.482M in 2026, $-33.916M in 2027, and $-32.405M in 2028.